**SUPPLEMENTARY MATERIAL**

**Author contributions:**

COM and PME designed the study and drafted the manuscript. The search strategy was developed by COM. Two independent reviewers (OG and MA) performed the literature search and checked the eligibility of each study. Disagreement between the two reviewing authors was resolved by a third author (COM). Data were extracted by COM and independently verified by MA. Post-publication data required for the completion of the systematic review/meta-analysis were provided by PV, MM, DM, CA, AF, JO, KL and AM. RO and ZA provided statistical expertise. The quality of the included studies was assessed by two reviewers (MA, COM).

**Definitions of predictors used in HCM Risk-SCD:**

1. Age at time of first evaluation (years)

2. Family history of SCD (FHSCD) in 1 or more first degree relatives under 40 years of age or SCD in a first degree relative with confirmed HCM (post- or ante-mortem diagnosis) at any age.

3. MWT in the parasternal short and long-axis plane using 2-D echocardiography (mm)

4. Left atrial diameter (LAd) by M-Mode or 2D echocardiography in the parasternal long axis plane (mm).

5. Maximal instantaneous left ventricular outflow tract gradient (LVOTgmax) at rest and with Valsalva provocation (irrespective of concurrent medical treatment) using continuous wave Doppler echocardiography (mmHg)

6. Non-sustained ventricular tachycardia (NSVT) defined as ≥3 consecutive ventricular beats at a rate of ≥120 beats per minute and <30s in duration on Holter monitoring (minimum duration 24 hours) at or prior to first evaluation.

**Papers excluded due to selective reporting of patient subgroups**

1. Ruiz-Salas A, Garcia-Pinilla JM, Cabrera-Bueno F, Fernandez-Pastor J, Pena-Hernandez J, Medina-Palomo C, Barrera-Cordero A, De Teresa E, Alzueta J. Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace 2015.
2. Rigopoulos AG, Daci S, Pfeiffer B, Papadopoulou K, Neugebauer A, Seggewiss H. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2016; 105:953-961.
3. Thavikulwat AC, Tomson TT, Knight BP, Bonow RO, Choudhury L. Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy. J Cardiovasc Electrophysiol 2016; 27:953-960.
4. Sugrue A, Killu AM, DeSimone CV, Chahal AA, Vogt JC, Kremen V, Hai J, Hodge DO, Acker NG, Geske JB, Ackerman MJ, Ommen SR, Lin G, Noseworthy PA, Brady PA. Utility of T-wave amplitude as a non-invasive risk marker of sudden cardiac death in hypertrophic cardiomyopathy. Open Heart 2017; 4:e000561.
5. Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Hansen PR, Seggewiss H, Horstkotte D, Adlova R, Michels M, Bundgaard H, Ten Berg JM, Veselka J. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation. Europace 2017.
6. Doesch C, Tulumen E, Akin I, Rudic B, Kuschyk J, El Battrawy I, Becher T, Budjan J, Smakic A, Schoenberg SO, Borggrefe M, Papavassiliu T. Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy. Sci Rep 2017; 7:6336.

**Papers excluded due to publication in Non-English language.**

1. Assessment of risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Attanasio P; Blaschke F; Pieske B; Tschope C; Haverkamp W. Deutsche medizinische Wochenschrift, (2016); 141 (14): 1035-9. Doi: 10.1055/s-0041-107679.
2. Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016. Dubourg O; Charron P; Sirol M; Siam-Tsieu V; Mansencal N. Presse medicale (Paris, France); (2016); 45(10): 903-910. Doi: 10.1016/j.lpm.2016.04.011.
3. Risk of sudden death according to the latest European guidelines on hypertrophic cardiomyopathy. Iacovoni A; Quarta G; Senni M. Giornale italiano di cardiologia (2006); 16(3): 143-6. Doi: 10.1714/1820.19820.
4. Clinical characteristics and outcome of patients with dilated-hypertrophic cardiomyopathy. Li PR; Li XL; Xu F; Gou C; Deng MJ; Liu JQ; Wang K; Zhonghua xin xue guan bing za zhi (2016); 44(4): 327-30. Doi: 10.3760/cma.j.issn.0253-3758.2016.04.010.
5. Therapeutische Umschau. Revue therapeutique. Muggli B; Gruner C (2016); Colume 73, Pages 759-765. ISBN 0040-5930 (Linking).
6. Feasibility of the 2014 European guidelines risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy in Chinese patients. Zhu SH; Li Y; Huang W; Jiang H; Li SN; Chen L; Huang S; Yu HS; Xu B. Zhonghua xin xue guan bing za zhi (2017); 45(5): 404-408. Doi: 10.3760/cma.j.issn.0253-3758.2017.05.008.

**Newcastle-Ottawa Scale: detailed breakdown**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Selection | Comparability | Outcome | Newcastle-Ottawa Score |
| O’ Mahony 2014 (HCM Risk-SCD) | \*\*\*\* | \* | \*\*\* | 8 |
| Vriesendorp et al 2015 | \*\*\*\* | \* | \*\*\* | 8 |
| Magri et al 2016 | \*\*\*\* | \* | \*\* | 7 |
| Fernandez et al 2016 | \*\*\*\* | \* | \*\*\* | 8 |
| Leong et al 2017 | \*\*\* | \* | \*\*\* | 7 |
| O’ Mahony 2017 (HCM-EVIDENCE) | \*\*\*\* | \* | \*\*\* | 8 |